# GSK

Source: https://onco.cc/companies/gsk/  
OnCo record `gsk` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GSK makes Jemperli, Zejula, and the twice-approved myeloma ADC Blenrep.

## Summary

GSK, based in London and listed as GSK, makes Jemperli, Zejula and the twice-approved myeloma antibody-drug conjugate Blenrep. Dostarlimab is best known for organ preservation in mismatch-repair-deficient rectal cancer, reported by Cercek in 2022, and for the RUBY trial in endometrial cancer; niraparib is its PARP inhibitor in ovarian cancer; belantamab mafodotin was re-approved in 2025; momelotinib was proved in MOMENTUM for myelofibrosis; and B7-H4 and B7-H3 ADCs come from Hansoh licences. OnCo also links it to the bivalent HPV vaccine, to WRN helicase in MSI-high cancers, and to Zai Lab and SR One. Whether dostarlimab can turn rectal organ preservation into a formal indication is the open question. Dostarlimab, niraparib and belantamab mafodotin have their own pages.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: Tesaro, Inc.; Tesaro; Bellus Health Inc. - a GSK company; Bellus Health
- HQ: London
- Type: pharma
- Website: https://www.gsk.com
- Ticker: GSK

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/GSK_plc
- Official website: https://www.gsk.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/), [Chlorambucil](https://onco.cc/drugs/chlorambucil/), [Cobolimab](https://onco.cc/drugs/cobolimab/), [Dostarlimab](https://onco.cc/drugs/dostarlimab/), [Feladilimab](https://onco.cc/drugs/feladilimab/), [GSK2256098](https://onco.cc/drugs/gsk2256098/), [HPV bivalent vaccine (types 16 and 18)](https://onco.cc/drugs/hpv-bivalent-vaccine/), [IDRX-42](https://onco.cc/drugs/idrx-42/), [Momelotinib](https://onco.cc/drugs/momelotinib/), [Niraparib](https://onco.cc/drugs/niraparib/), [Ondansetron](https://onco.cc/drugs/ondansetron/), [Topotecan](https://onco.cc/drugs/topotecan/), [Velzatinib](https://onco.cc/drugs/velzatinib/)
- trials: [A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer](https://onco.cc/trials/nct03602859/), [A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study](https://onco.cc/trials/nct04641247/), [A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202](https://onco.cc/trials/nct06062420/), [A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer](https://onco.cc/trials/nct05565378/), [A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)](https://onco.cc/trials/nct07602777/), [A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas](https://onco.cc/trials/nct06679101/), [A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06472076/), [A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer](https://onco.cc/trials/nct06521567/), [A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors](https://onco.cc/trials/nct07263594/), [A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)](https://onco.cc/trials/nct07108270/), [A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer](https://onco.cc/trials/nct06317311/), [A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China](https://onco.cc/trials/nct06640049/), [A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct06256588/), [A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer](https://onco.cc/trials/nct06990880/), [A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)](https://onco.cc/trials/nct07099898/), [A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy](https://onco.cc/trials/nct07218926/), [A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)](https://onco.cc/trials/nct06796907/), [A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer](https://onco.cc/trials/nct06567782/), [A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)](https://onco.cc/trials/nct07602855/), [A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07740720/), [A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib](https://onco.cc/trials/nct07689201/), [A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult](https://onco.cc/trials/nct07227311/), [A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)](https://onco.cc/trials/nct07286331/), [A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)](https://onco.cc/trials/nct07286266/), [A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme](https://onco.cc/trials/nct05714839/), [A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors](https://onco.cc/trials/nct07213609/), [A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors](https://onco.cc/trials/nct06710847/), [A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors](https://onco.cc/trials/nct06077877/), [A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)](https://onco.cc/trials/nct07585266/), [A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)](https://onco.cc/trials/nct06885034/), [All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo](https://onco.cc/trials/nct06956170/), [Alliance A071401](https://onco.cc/trials/a071401/), [China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame](https://onco.cc/trials/nct06868654/), [COMBI-d](https://onco.cc/trials/combi-d/), [Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease](https://onco.cc/trials/nct04915755/), [Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy](https://onco.cc/trials/nct04655976/), [Extended Access of Momelotinib in Adults With Myelofibrosis](https://onco.cc/trials/nct03441113/), [First-Time-in-Human Study of GSK5471713 in Adults With mCRPC](https://onco.cc/trials/nct07332455/), [GARNET](https://onco.cc/trials/garnet/), [Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex](https://onco.cc/trials/nct06868667/), [MOMENTUM](https://onco.cc/trials/momentum/), [PATRICIA](https://onco.cc/trials/patricia/), [Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple](https://onco.cc/trials/nct04126200/), [Study 3 (rolapitant, moderately emetogenic chemotherapy)](https://onco.cc/trials/ts-p04834/), [Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer](https://onco.cc/trials/nct05855200/), [Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple](https://onco.cc/trials/nct04162210/), [Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi](https://onco.cc/trials/nct07150104/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM](https://onco.cc/trials/nct07217119/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM](https://onco.cc/trials/nct07217184/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM](https://onco.cc/trials/nct07084896/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM](https://onco.cc/trials/nct07150091/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- key papers: [Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency](https://onco.cc/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/), [Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis](https://onco.cc/key-papers/paper-patricia-paavonen-lancet-2009/), [MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor](https://onco.cc/key-papers/paper-momentum-momelotinib-lancet-2023/), [Nonoperative management of mismatch repair-deficient tumors](https://onco.cc/key-papers/paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025/), [RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer](https://onco.cc/key-papers/paper-ruby-nejm-2023/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/)
- targets: [WRN helicase (MSI-high cancers)](https://onco.cc/targets/wrn/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/), [SR One](https://onco.cc/companies/sr-one/), [Zai Lab](https://onco.cc/companies/zai-lab/)

---
JSON: https://onco.cc/api/v1/entities/gsk.json